Literature DB >> 2551482

An ultrastructural evaluation of cell heterogeneity in invasive ductal carcinomas of the human breast. II. An in vitro study.

I Pucci-Minafra1, S Minafra, R Alessandro, A M Faccini.   

Abstract

The ultrastructural characterization of the present continuous cell line, derived from a primary ductal infiltrating carcinoma (d.i.c.) of the human breast, has brought to light a remarkable morphological similarity with the original neoplastic cell population. A major parallelism is the permanent presence in culture of two categories of cells, exhibiting a strong isomorphism with the in vivo counterparts. The presence of well defined ultrastructural features, as duct-like structures, microvillous projections, junctional complexes and intracytoplasmic crypts, is a further confirmation of the breast cancer origin of this line. The significance and perspective of these findings are discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2551482

Source DB:  PubMed          Journal:  J Submicrosc Cytol Pathol        ISSN: 1122-9497


  3 in total

1.  Routine culturing of normal, dysplastic and malignant human mammary epithelial cells from small tissue samples.

Authors:  J T Emerman; D A Wilkinson
Journal:  In Vitro Cell Dev Biol       Date:  1990-12

2.  Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasis.

Authors:  Riccardo Alessandro; Maria Antonietta Di Bella; Anna Maria Flugy; Simona Fontana; Francesca Damiani; Chiara Corrado; Paolo Colomba; Matilde Todaro; Domenica Russo; Alessandra Santoro; Elise C Kohn; Giacomo De Leo
Journal:  Virchows Arch       Date:  2006-04-13       Impact factor: 4.064

3.  Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells.

Authors:  Jennifer L Gilmore; Jeffrey A Scott; Zhor Bouizar; Alex Robling; Sarah E Pitfield; David J Riese; John Foley
Journal:  Breast Cancer Res Treat       Date:  2007-09-20       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.